Compare Banco Santander SA (SAN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs Viatris Inc — how do they compare? Banco Santander SA trades at $13.5 (market cap $192.86B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Banco Santander SA is far larger — about 9.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and Viatris Inc for 57 Days on average.
| SAN | VTRS | |
|---|---|---|
Market Cap | $192.86B | $20.03B |
Volume | 10,644,519 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $15.05 | $18.27 |
52-Week Low | $9.65 | $9.74 |
Typical Hold Time | 55 Days | 57 Days |
Enterprise Value | $360.86B | $32.15B |
Dividend Yield | 2.06% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.49, down 1.24% with bearish technical signals, though fundamentals show strength with 26.25% net margins and 16.07% ROE. Recent earnings show mixed quarterly performance, beating in Q1 but missing in Q2. The company completed the Webster Bank acquisition in August 2026, expanding U.S. presence and driving record profits. Cash flow trends remain negative, but revenue and net income have grown steadily from 2022-2026.
Outlook remains cautiously optimistic with 64% analyst buy ratings supporting growth potential from strategic acquisitions and digital transformation. Key risks include negative cash flow trends, high debt levels at $288B, and economic sensitivity. The stock offers value at 13.55 P/E but requires monitoring of operational cash flow recovery and integration of recent acquisitions.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
